Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%. Several blockbuster products are due to undergo patent expiry over the forecast period and the loss of their branded sales will negatively impact on the growth of this market. But the launch of a number of drugs in rare indications will stabilize growth in this market and offset its decline from generic entry.
Key reasons to purchase this title
- Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2009 to 2019
- Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth
- Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot
